- Previous Close
7.25 - Open
7.30 - Bid 7.35 x --
- Ask 7.40 x --
- Day's Range
7.15 - 7.45 - 52 Week Range
6.00 - 13.80 - Volume
2,414,464 - Avg. Volume
10,869,295 - Market Cap (intraday)
7.85B - Beta (5Y Monthly) --
- PE Ratio (TTM)
18.85 - EPS (TTM)
0.39 - Earnings Date --
- Forward Dividend & Yield 0.32 (4.35%)
- Ex-Dividend Date May 6, 2025
- 1y Target Est
12.00
Medeze Group Public Company Limited engages in collection and storage of stem cells for use in medication in Thailand, Vietnam, Cambodia, and internationally. The company operates through four segments: Stem Cells; Natural Killer Cells; Others; and Sales of Products. It also provides sorting, cultivation, and development of stem cells; testing services to test the performance and count the number of natural killer cells; and research, develops, and collects data on all types of human cellular activities and medical laboratory test. In addition, the company sells dietary supplements, cosmetics, and dermo cosmetics. The company was founded in 2010 and is based in Nakhon Pathom, Thailand.
www.medezegroup.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MEDEZE.BK
View MorePerformance Overview: MEDEZE.BK
Trailing total returns as of 4/18/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MEDEZE.BK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MEDEZE.BK
View MoreValuation Measures
Market Cap
7.74B
Enterprise Value
5.66B
Trailing P/E
18.59
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.34
Price/Book (mrq)
2.65
Enterprise Value/Revenue
6.83
Enterprise Value/EBITDA
13.73
Financial Highlights
Profitability and Income Statement
Profit Margin
38.74%
Return on Assets (ttm)
10.23%
Return on Equity (ttm)
19.37%
Revenue (ttm)
874.33M
Net Income Avi to Common (ttm)
338.74M
Diluted EPS (ttm)
0.39
Balance Sheet and Cash Flow
Total Cash (mrq)
2.1B
Total Debt/Equity (mrq)
0.84%
Levered Free Cash Flow (ttm)
-116.71M